Clinical trials
Breast Cancer Recurrent clinical trials
Below are recruiting breast cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 634 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06335069RecruitingPhase 2
Comparing two PET tracers in ER-positive breast cancer
This trial compares two types of PET scans to see which one better detects ER-positive breast cancer. The results could help doctors choose the best scan for tracking your cancer.
MaastrichtAges 18 years+ - NCT06362616Recruiting
Pre-surgery partial breast radiation for recurrent breast cancer
This trial tests a shorter course of radiation to just part of the breast before surgery for women who have had breast cancer return in the same breast. It's for those who have already had radiation to that breast and have a specific type of cancer (ER+, HER2-).
AmsterdamAges 51 years+ - NCT06367088RecruitingPhase 2
Combination drug therapy for advanced triple-negative breast cancer
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
Wuhan, HubeiAges 18–70 - NCT06371768Recruiting
Helping Young Cancer Survivors Manage Symptoms & Transition to Care
This study is designed to help adolescent and young adult cancer survivors manage symptoms and smoothly transition to post-treatment care. If you finished treatment for certain cancers within the past 1 to 5 years, you may be able to join.
Durham, North CarolinaAges 18–39 - NCT06387628RecruitingPhase 2
LM-108 with immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06404983Recruiting
Opioid-free anesthesia for breast cancer surgery
This study tests whether breast cancer surgery can be done safely without using opioid pain medicines during anesthesia. The goal is to see if avoiding opioids leads to fewer side effects and a smoother recovery.
Ioannina, EpirusAges 18–99 - NCT06430541RecruitingPhase 1
Psilocybin therapy for fear of cancer recurrence
This trial tests if psilocybin-assisted therapy can help reduce the intense worry that cancer might come back. It is for people who have finished their main treatments for early-stage breast cancer or advanced ovarian cancer.
Aurora, ColoradoAges 21 years+ - NCT06446882Recruiting
HER2DX test to guide treatment for early HER2+ breast cancer
This trial tests whether a new test (HER2DX) can help doctors choose the best treatment combination for HER2-positive breast cancer before surgery. It's for people whose cancer hasn't spread and who haven't started therapy yet.
GrazAges 18 years+ - NCT06452706RecruitingPhase 2
Study of TQB2102 for HER2-negative breast cancer that has spread
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
Bozhou, AnhuiAges 18–75 - NCT06471673RecruitingPhase 1/Phase 2
BRIA-OTS cellular immunotherapy for metastatic breast cancer
This study tests an investigational cellular immunotherapy called BRIA-OTS for people with metastatic breast cancer that has spread and is no longer responding to standard treatments. It aims to help the immune system fight cancer cells.
Santa Monica, CaliforniaAges 18 years+ - NCT06476119Recruiting
Optimizing treatment for low stage triple-negative breast cancer with high immune cells
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
Sittard-Geleen, LimburgAges 18 years+ - NCT06587789Recruiting
Ribociclib plus hormone therapy for high-risk breast cancer
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
Hangzhou, ZhejiangAges 18–80 - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Sarasota, FloridaAges 18 years+ - NCT06508216RecruitingPhase 1/Phase 2
New drug combo for early relapsed triple-negative breast cancer
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
VillejuifAges 18 years+ - NCT06517212RecruitingPhase 2
Tirzepatide for weight loss in MRD-positive early breast cancer
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
Dallas, TexasAges 18 years+ - NCT06545331RecruitingPhase 1
A study of XB010 for advanced solid tumors
This trial tests an investigational drug called XB010 for people with solid tumors that have spread or cannot be removed by surgery. It aims to see if XB010 is safe and effective for several cancer types, including lung, breast, head and neck, and esophageal cancers.
Irvine, CaliforniaAges 18 years+ - NCT06547840RecruitingPhase 1
Study of MOv18 IgE for ovarian, endometrial, and breast cancers with a specific marker
This trial tests a new antibody treatment called MOv18 IgE for patients with advanced ovarian, endometrial, or triple-negative breast cancers that have a protein called folate receptor alpha (FRα) on their tumor cells. The goal is to see if the treatment is safe and effective.
BristolAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Little Rock, ArkansasAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant vs standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
Daphne, AlabamaAges 18 years+ - NCT06606730RecruitingPhase 3
Personalized pembrolizumab after strong chemo response for early triple-negative breast cancer
This trial is for people with early triple-negative breast cancer who had a strong response to chemotherapy combined with pembrolizumab before surgery. It aims to find the best way to continue using pembrolizumab after surgery to reduce the risk of cancer coming back.
BrusselsAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06635980RecruitingPhase 2
Radiation before or after breast cancer surgery
This trial compares two ways of giving radiation for breast cancer that has not spread: before or after surgery. It aims to see if giving radiation first might work as well or better.
Scottsdale, ArizonaAges 18 years+ - NCT06642545RecruitingPhase 2
New targeted drug combo for HER2-low breast cancer
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Breast Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer recurrent?
- Yes. Clin2 currently lists 634 recruiting breast cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.